A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Shares of Exelixis, Inc. EXEL have risen 20.7% in the past three months compared with the industry’s growth of 6.3%. The ...
Zacks.com on MSN10h
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
RBC Capital analyst Gregory Renza maintained a Buy rating on Exelixis (EXEL – Research Report) yesterday and set a price target of ...
In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...
Cabometyx is already approved as a second-line treatment for HCC in people who have previously received Nexavar, along with first- and second-line approvals for RCC, with sales reaching $720 ...
--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX ®) in ...
Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback